Sh-proteinases (3.4.22) (e.g., Papain, Chymopapain, Bromelains, Ficin, Etc.) Patents (Class 424/94.65)
  • Patent number: 10525069
    Abstract: The embodiments relate to compositions useful in the treatment, inhibition or prevention of urinary tract infection in a subject. The compositions comprise a pH increasing agent, a pH decreasing agent and man nose or an analogue thereof. The pH increasing agent and the pH decreasing agent are provided to be alternately administered to the subject.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: January 7, 2020
    Assignee: BIOMEDICALS SWEDEN AB
    Inventor: Constantin Raduti
  • Patent number: 10206982
    Abstract: Wound debridement compositions containing the proteolytic enzyme Seaprose and use of such compositions in wound treatment for the enzymatic debridement of wounds.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: February 19, 2019
    Assignee: SMITH & NEPHEW ORTHOPAEDICS AG
    Inventors: Lei Shi, Aleksa Jovanovic, Dennis Carson
  • Patent number: 10123759
    Abstract: Pain factors are labeled with targeted agents or markers delivered into the body. The labeled pain factors are imaged with appropriate imaging tools in a manner allowing selective identification and localization of areas of pain source or transmission. The labeled pain factors allow spatial differentiation in the imaging sufficient to specify the location of the pain so as to drive therapeutic decisions and techniques in order to treat the pain. Pain factors labeled and imaged in this manner may include one or more of nerve factors, blood vessel factors, cellular factors, and inflammation factors. Labeled markers may include for example radioactive materials (e.g. tritiated or iodinated molecules) or other materials such as metal (e.g. gold) nanoparticles. Intermediary binding materials may be used, such as for example bi-specific antibodies.
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: November 13, 2018
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: David S. Bradford, Jeffrey C. Lotz
  • Patent number: 10076540
    Abstract: Embodiments described herein generally relate to medicinal compositions (e.g., compositions comprising an active pharmaceutical agent) such as those comprising liquid hydrogen and/or hydrogen gas. In certain embodiments, the composition comprises hydrogen and/or noble gas(es) in a medicinal composition, for example, within the aqueous phase (e.g., dissolved). For example, in some cases, the medicinal composition may comprise an active pharmaceutical ingredient and hydrogen (H2) and/or noble gas(es). The noble gas may be, for example, xenon, argon, or the like. In some embodiments, the hydrogen and/or the noble gas(es) may infuse with the composition (e.g., such that at least a portion of the hydrogen gas and/or noble gas(es) is dissolved within the composition). Such compositions comprising hydrogen gas and/or noble gas(es) may be useful, for example, for the treatment of animal and human diseases, for improvement in athletic performance, for the enhancement of the overall health of a subject, or the like.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: September 18, 2018
    Assignee: Perricone Hydrogen Water Company, LLC
    Inventor: Nicholas V. Perricone
  • Patent number: 9770434
    Abstract: A nutritional supplement is provided comprising alpha-lipoic acid and curcumin. The nutritional supplement may be used for reducing weight or reducing weight gain, for reducing fat or reducing fat gain, for reducing loss in lean mass or maintaining lean mass, or for reducing loss of appetite or for maintaining appetite.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: September 26, 2017
    Assignee: Northern Innovations Holding Corp
    Inventors: Debasis Bagchi, John Doherty, Philip Apong, Vaishali Joshi, Jason Peters
  • Patent number: 9663777
    Abstract: The invention relates to a component of bromelain which is largely responsible for the ability of bromelain to interrupt the MAP kinase cascade. The component contains ananain and comosain and is useful in the treatment or prevention of diseases and conditions mediated by T cell activation or by activation of the MAP kinase pathway.
    Type: Grant
    Filed: October 12, 2010
    Date of Patent: May 30, 2017
    Assignee: Sarantis Pty Ltd
    Inventors: Tracey Lehanne Mynott, Christian Engwerda, Keith Peek
  • Publication number: 20150147308
    Abstract: Described herein are compositions which include digestive enzymes and which are formulated to reduce one or more symptoms of a neuropsychiatric disorder. Also described herein is a method for treating an individual with a neuropsychiatric disorder using digestive enzymes and their derivatives to alleviate the symptoms of neuropsychiatric disorders. The method comprises administering to the individual an effective amount of digestive enzymes that are either naturally or recombinantly derived, or their derivatives, in an amount effective to reduce one or more symptoms of the neuropsychiatric disorder.
    Type: Application
    Filed: February 3, 2015
    Publication date: May 28, 2015
    Inventors: Joan M. Fallon, Matthew Heil, James Szigethy, James Fallon
  • Patent number: 9028814
    Abstract: Beneficial and synergistic effects for alleviating joint pain and symptoms of osteoarthritis and/or rheumatoid arthritis have been found using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated EPA and DHA either alone or in combination with other active constituents, including astaxanthin and polymeric hyaluronic acid or sodium hyaluronate (hyaluronan) in an oral dosage form.
    Type: Grant
    Filed: September 5, 2013
    Date of Patent: May 12, 2015
    Assignee: U.S. Nutraceuticals, LLC
    Inventors: John A. Minatelli, W. Stephen Hill, Rudi E. Moerck
  • Patent number: 9017665
    Abstract: A therapeutic agent for the treatment of the symptoms of addiction and the method for preparing the therapeutic agent is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using of a biomarker, the presence of chymotrypsin in the gastrointestinal tract to determine the presence of symptoms of addiction, and the likelihood of relapsing into addiction is disclosed.
    Type: Grant
    Filed: June 25, 2013
    Date of Patent: April 28, 2015
    Assignee: Curemark, LLC
    Inventor: Joan M. Fallon
  • Patent number: 9017667
    Abstract: The therapeutic efficacy of zymogen proteins for oral administration is improved by including in the formulation one or more excipients that optimize pH and other reaction conditions for rapid activation of the zymogen shortly after ingestion.
    Type: Grant
    Filed: October 9, 2009
    Date of Patent: April 28, 2015
    Assignee: Alvine Pharmaceuticals, Inc.
    Inventor: Bret Berner
  • Patent number: 8980254
    Abstract: Pharmaceutical formulations of orally administered proteins can be stabilized from oxidative degradation and inactivation in the stomach and GI tract by the addition of an antioxidant.
    Type: Grant
    Filed: August 21, 2009
    Date of Patent: March 17, 2015
    Assignee: Alvine Pharmaceuticals, Inc.
    Inventors: Matthew John Siegel, Bret Berner
  • Publication number: 20150071993
    Abstract: Provided are supplemental compositions for a nutraceutical formulation and methods for administering the same to a user for inducing or maintaining sleep as well as for alleviating pain to improve sleep using a formulation of ingredients comprising of extract of ashwagandha, extract of lavender, extract of valerian, extract of hops, melatonin, magnesium, vitamin B12, and zinc, and/or devil's claw, bromelain and boswellia.
    Type: Application
    Filed: September 8, 2014
    Publication date: March 12, 2015
    Inventors: Amit Patel, Timothy Warbington
  • Publication number: 20150071879
    Abstract: An aqueous composition having increased protein stability is obtained by: a. determining a pH at which the protein has stability at the desired temperature; b. adding to the composition at least one displacement buffer wherein the displacement buffer has a pKa that is at least 1 unit greater or less than the pH of step (a); and c. adjusting the pH of the composition to the pH of step (a); wherein the aqueous composition does not comprise a conventional buffer at a concentration greater than about 2 mM and wherein the conventional buffer has a pKa that is within 1 unit of the pH of step (a).
    Type: Application
    Filed: October 17, 2014
    Publication date: March 12, 2015
    Inventor: Jan JEZEK
  • Publication number: 20150064163
    Abstract: The invention relates to truncated growth factors and variants thereof. The invention also relates to methods of making and using the truncated growth factors. The invention further relates to compositions including a protease and a growth factor comprising a bone morphogenic protein (BMP) or a variant thereof. The invention also relates to methods of using the composition.
    Type: Application
    Filed: September 2, 2012
    Publication date: March 5, 2015
    Applicant: LIFENET HEALTH
    Inventors: Xiaofei Qin, Silvia Chen, Jingsong Chen, James Clagett
  • Publication number: 20150037315
    Abstract: The present invention relates to a dietary supplement and methods of use thereof. More particularly, the invention relates to a composition including a kiwifruit extract in combination with an amylase inhibitor and/or a bifunctional protease-amylase inhibitor, particularly, but not exclusively, for managing gut health or for the treatment or prevention of digestive dysfunction, gastrointestinal disorders or symptoms thereof.
    Type: Application
    Filed: May 16, 2012
    Publication date: February 5, 2015
    Applicant: VITAL FOOD PROCESSORS LIMITED
    Inventors: Kawal Matharu, Iona Weir
  • Publication number: 20140363377
    Abstract: The invention provides compositions and method for delivering a therapeutic or diagnostic agent to a disease site in a mammal, the method comprising administering to the mammal a therapeutically or diagnostically effective amount of a pharmaceutical composition, wherein the pharmaceutical composition comprises the therapeutic or diagnostic agent coupled to a Procaspase 8 polypeptide and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: June 18, 2014
    Publication date: December 11, 2014
    Inventor: Isabella TAI
  • Publication number: 20140363420
    Abstract: A method, product by process, and composition for aiding in pain relief. The user adds hot water to methylsulfonylmethane (MSM), then stirs the resulting mixture until the MSM is dissolved. The user then adds room temperature water, bromelain, aloe vera juice, and papain to the batch, and continues to stir. Coconut oil and palm kernel oil are stirred in, along with a sweet oil mixture. The sweet oil mixture is a mixture of natural, unconcentrated, oils such as lemon oil, sweet orange oil, arnica, sweet almond oil, peppermint oil, grape seed oil, comfrey oil, eucalyptus oil, grapefruit seed extract, and fragrance oils such as mango and kiwi. Finally, xanthan gum is stirred into the mixture, resulting in a batch of desired composition, which can be used topically for pain relief.
    Type: Application
    Filed: June 5, 2014
    Publication date: December 11, 2014
    Inventors: Mark A. LANNES, Lisa C. LANNES, Joe D. STUBBLEFIELD
  • Publication number: 20140341880
    Abstract: Methods for assessing a risk of experiencing an adverse perinatal outcome in a subject are described. The methods include determining a level of at least one cytokine in a biological sample from the subject; and comparing the level of the at least one cytokine in the subject's biological sample with a predetermined value based on levels of the at least one cytokine in a biological sample from a population of control subjects, wherein a subject whose level of at least one cytokine is greater than the predetermined line value is at risk of experiencing an adverse perinatal outcome.
    Type: Application
    Filed: September 17, 2012
    Publication date: November 20, 2014
    Inventors: Sheryl Sue Justice, Santiago Partida-Sanchez
  • Publication number: 20140308265
    Abstract: The claimed invention is directed to compositions and methods effective in preventing microbial contamination or reducing microbial count associated with a contaminated surface, comprising a biocidal system comprised of a primary biocide, a pH buffer agent, a surfactant, all in an aqueous based carrier, wherein the compositions may be considered environmentally friendly.
    Type: Application
    Filed: November 6, 2012
    Publication date: October 16, 2014
    Inventors: Burt R. Sookram, John W. Veenstra
  • Publication number: 20140286929
    Abstract: Provided herein are novel biomarkers for the identification, prediction or monitoring of fibrotic pulmonary diseases (e.g. idiopathic pulmonary fibrosis (IPF)). The biomarkers provided herein may further be used for therapeutic treatment of IPF.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 25, 2014
    Applicant: Intermune, Inc.
    Inventors: Karl Kossen, Xiaoli Qin, Sharlene R. Lim, Scott S. Seiwert, Donald Ruhrmund
  • Publication number: 20140271609
    Abstract: Methods and combinations are provided for controlling the duration of action, in vivo, of matrix-degrading enzymes. The methods and combinations permit temporary in-vivo activation of matrix-degrading enzymes upon administration to the extra cellular matrix (or “ECM”). Matrix-degrading enzymes having a controlled duration of action can be used to treat ECM-mediated diseases or disorders characterized by increased deposition or accumulation of one or more ECM components.
    Type: Application
    Filed: April 2, 2014
    Publication date: September 18, 2014
    Inventors: Gilbert Keller, Gregory I. Frost
  • Publication number: 20140271608
    Abstract: Aspects of the invention include methods for treating or preventing a thromboembolic disease in a subject. In practicing methods according to certain embodiments, an amount of a low molecular weight heparin (LMWH) and a synergistically effective combination of two or more gastrointestinal epithelial barrier permeation enhancers is orally administered to a subject in a manner sufficient to treat the thromboembolic disease in the subject. Compositions and kits for practicing methods of the invention are also described.
    Type: Application
    Filed: January 21, 2014
    Publication date: September 18, 2014
    Applicants: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.
    Inventors: Peter Turecek, Susanne Vejda
  • Publication number: 20140248258
    Abstract: The present invention provides methods for improving gut health. In particular, the invention provides methods for improving gut health by improving the digestibility of dietary proteins, decreasing the flow of protein to the lower gastrointestinal tract, and/or decreasing the levels of Clostridium bacteria the upper intestinal tract of a subject. The methods comprise administering to the subject a supplement consisting essentially of at least one protease.
    Type: Application
    Filed: May 15, 2014
    Publication date: September 4, 2014
    Applicant: NOVUS INTERNATIONAL, INC.
    Inventors: Chris D. Knight, Julia J. Dibner, Fenglan Yan
  • Patent number: 8821862
    Abstract: The present invention provides compositions comprising an antibiofilm enzyme, a soluble ?-N-acetylglucosaminidase similar to the dspB gene (DispersinB®), and an antimicrobial for preventing growth and proliferation of biofilm-embedded microorganisms in acute and chronic wounds, and methods of treatment. The invention further provides methods for preparing medical devices, and in particular, wound care devices using soluble ?-N-acetylglucosaminidase based antimicrobial compositions.
    Type: Grant
    Filed: March 9, 2012
    Date of Patent: September 2, 2014
    Assignees: Kane Biotech Inc., University of Medicine and Dentistry of New Jersey
    Inventors: Srinivasa Madhyastha, Nanda Yakandawala, Purushottam V. Gawande, Karen Lovetri, Jeffrey B. Kaplan, Daniel Rhoads, Lasha Gogokhia
  • Publication number: 20140170106
    Abstract: The methods and compositions disclosed herein are effective in the promoting the reattachment of delaminated cartilage to bone. The methods (and related compositions) comprise the removal of the acellular layer of the delaminated cartilage thereby exposing the underlying chondrocyte cells thereby allowing the promotion of the reattachment of the delaminated cartilage.
    Type: Application
    Filed: November 8, 2013
    Publication date: June 19, 2014
    Inventors: Kelsey Jean Carvell, Ruth Cheng, Graham Smith, Drew Burdon
  • Publication number: 20140161789
    Abstract: A product containing papain, bromelain or mixtures thereof is intended for use as a medicinal product at a dosage of at least 5000 mg administered for at least one day in a single dose. This dosage relates to papain powder having a titre of 3 U/mg and bromelain powder having a titre of 2 U/mg, and to a patient with a body weight of 55 kg. In the case of variations of the titre and/or of the patient's weight, the dosage must be varied in proportion to said variations.
    Type: Application
    Filed: December 28, 2012
    Publication date: June 12, 2014
    Inventors: Giuseppe CARPIGNOLI, Alberto DI GIOVANNI
  • Publication number: 20140161787
    Abstract: A therapeutic agent for the treatment of the symptoms of addiction and the method for preparing the therapeutic agent is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using of a biomarker, the presence of chymotrypsin in the gastrointestinal tract to determine the presence of symptoms of addiction, and the likelihood of relapsing into addiction is disclosed.
    Type: Application
    Filed: June 25, 2013
    Publication date: June 12, 2014
    Applicant: CUREMARK LLC
    Inventor: Joan M. Fallon
  • Publication number: 20140154229
    Abstract: The present invention relates to a proteolytic extract obtained from bromelain for the treatment of connective tissue diseases. In particular, the present invention relates to a pharmaceutical composition that includes proteolytic extract obtained from bromelain for the treatment of diseases such as Dupuytren's disease and Peyronie's disease.
    Type: Application
    Filed: July 19, 2012
    Publication date: June 5, 2014
    Inventors: Lior Rosenberg, Guy Rubin, Eilon Asculai
  • Publication number: 20140147433
    Abstract: The methods and devices disclosed herein are effective in the promoting the reattachment of delaminated cartilage to bone. The methods (and related devices) are effective in the removal of the acellular layer of the delaminated cartilage or effective in the indentation of the acellular layer of the delaminated cartilage thereby exposing the underlying chondrocyte cells and thereby allowing the promotion of the reattachment of the delaminated cartilage.
    Type: Application
    Filed: November 8, 2013
    Publication date: May 29, 2014
    Inventors: Kelsey Jean Carvell, Ruth Cheng, Graham Smith, Drew Burdon, Paul Alexander Torrie
  • Publication number: 20140037748
    Abstract: The invention provides methods of making and using compositions comprising a polymer shell designed to deliver polypeptides to selected environments. In embodiments of the invention, different environmental conditions are harnessed to allow the selective degradation of the polymer shell and the consequential release of one or polypeptides encapsulated therein. In illustrative embodiments, polymer components of the shell are interconnected by disulfide-containing crosslinker moieties, linkages which maintain the integrity of the polymer shell under certain environmental conditions including those occuring outside of cells, but degrade in an intracellular environment.
    Type: Application
    Filed: April 13, 2012
    Publication date: February 6, 2014
    Applicant: The Regents of the University of California
    Inventors: Yi Tang, Zhen Gu, Muxun Zhao
  • Publication number: 20140030333
    Abstract: A therapeutic agent for the treatment of toxemia, preeclampsia and eclampsia and the method for preparing the therapeutic agents is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using of a biomarker, the presence of chymotrypsin in the maternal GI tract to determine the likelihood of developing preeclampsia, pregnancy induced hypertension, and eclampsia/toxemia is disclosed.
    Type: Application
    Filed: September 26, 2013
    Publication date: January 30, 2014
    Applicant: CUREMARK, LLC
    Inventor: Joan M. Fallon
  • Publication number: 20140023634
    Abstract: Beneficial and synergistic effects for alleviating joint pain and symptoms of osteoarthritis and/or rheumatoid arthritis have been found using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated EPA and DHA either alone or in combination with other active constituents, including astaxanthin and polymeric hyaluronic acid or sodium hyaluronate (hyaluronan) in an oral dosage form.
    Type: Application
    Filed: September 5, 2013
    Publication date: January 23, 2014
    Applicant: U.S. NUTRACEUTICALS, LLC d/b/a Valensa International
    Inventors: John A. MINATELLI, W. Stephen Hill, Rudi E. Moerck
  • Patent number: 8617542
    Abstract: The present invention provides antibiofilm composition comprising two or more agents selected from the group consisting of DispersinB™, 5-Fluorouracil, Deoxyribonuclease I and Proteinase K for preventing growth and proliferation of biofilm-embedded microorganisms in wound care, oral care, and disease-related infections and methods of treatment in mammals. The invention further provides methods for preparing medical devices, and wound care devices using an antibiofilm composition comprising two or more antimicrobial agents selected from the group consisting of DispersinB™, 5-Fluorouracil, Deoxyribonuclease I and Proteinase K.
    Type: Grant
    Filed: April 3, 2009
    Date of Patent: December 31, 2013
    Assignee: Kane Biotech Inc.
    Inventors: Srinivasa Madhyastha, Purusbottam Gawande, Karen Lovetri, Nandadeva Yakandawala, Jeffrey Kaplan
  • Publication number: 20130344145
    Abstract: A pharmaceutical composition or formulation adapted for oral administration in tablet, coated tablet, capsule or reconstitutable powder form for the prevention or treatment of intestinal disorders such irritable bowel syndrome, also known as irritable colon syndrome, based on an intestinal motility modifier, an agent that prevents gas retention, of digestive enzymes, a binding agent, a diluting agent, an absorbent agent, a lubricant, aglidant, and an disintegrating agent or suspending agent, effective in the normalization of intestinal disorders, to achieve an analgesic activity, to achieve an anti-spasmic activity and to reduce the symptoms associated with intestinal gas such as distention, abdominal pain and flatulence.
    Type: Application
    Filed: November 15, 2011
    Publication date: December 26, 2013
    Applicant: Posi Visionary Solutions LLP
    Inventor: Alana Noelle Denise Savoir Garcia
  • Publication number: 20130287830
    Abstract: Vehicles for delivery and release of pesticide compositions are provided. In one aspect, the delivery vehicle is a capsule configured to resist release of a pesticide composition before application of the capsule at a locus where pest control is desired. The capsule is further configured to degrade following application at the locus where pest control is desired to facilitate release of the pesticide composition. In one particular but non-limiting form, the capsule includes a shell wall including a relatively high Bloom strength gelatin material and a plasticizer material, and the pesticide composition includes a fumigant such as 1,3-dichloropropene. Further embodiments, forms, objects, features, advantages, aspects, and benefits shall become apparent from the description and drawings.
    Type: Application
    Filed: April 25, 2013
    Publication date: October 31, 2013
    Applicant: Dow AgroSciences LLC
    Inventors: Lorenzo Aulisa, John D. Busacca, Donald E. Williams,, III, Phillip J. Howard, Ashish Batra, Sara J. Linder
  • Publication number: 20130287757
    Abstract: An effective composition is for the therapeutic or cosmetic treatment of atrophic cutaneous and subcutaneous tissues, skin appendages, connective tissues or mucous tissues. The composition includes a combination of a salt of adamantane carboxylic acid, preferably salified with an aromatic and/or adamantane base, with a proteolytic enzyme and/or willow extract, salicylic acid, acetylsalicylic acid, salicylate, or acetylsalicylate. Further active ingredients that are suitable for inclusion in the composition are zinc oxide, vitamins, phytoextracts, sugars, amino acids, minerals, further salts, phytoextracts, ventilated green clay and any combination thereof. The composition has a particular synergy between the constituent elements, and is particularly effective in the treatment of atrophic ulcers or bedsores.
    Type: Application
    Filed: January 13, 2011
    Publication date: October 31, 2013
    Applicant: MEDESTEA INTERNAZIONALE S.P.A.
    Inventors: Luisa Gennero, Fulvio Pedrini, Maurizio Pedrini, Gianfranco Merizzi
  • Patent number: 8557237
    Abstract: A crème for use in connection with the treatment and prevention of ingrown hair. The crème basically comprises a carrier, preferably water and an active amount of encapsulated bromelain, the encapsulated bromelain preferably comprising an inert silicone, preferably cyclomethicone. Other components can be added to the composition, for example, beeswax, sunflower seed oil, shea butter and/or Tea Tree oil. The crème can be used to treat acne, as well.
    Type: Grant
    Filed: January 13, 2009
    Date of Patent: October 15, 2013
    Assignee: MindfulnessFYB, Inc.
    Inventors: Venue C. Borden, Carol Artiss
  • Publication number: 20130266556
    Abstract: Biomass (e.g., plant biomass, animal biomass, microbial, and municipal waste biomass) is processed to produce useful products, such as food products and amino acids.
    Type: Application
    Filed: November 9, 2010
    Publication date: October 10, 2013
    Applicant: XYLECO, INC.
    Inventor: Marshall Medoff
  • Patent number: 8540983
    Abstract: The present invention relates to a debriding composition obtained from bromelain and to methods of producing same. Particularly, the present invention relates to a debriding composition obtained from bromelain comprising proteolytic enzymes having molecular weights of about 23 kDa, being essentially devoid of bromelain inhibitors, and to pharmaceutical compositions comprising same. The debriding compositions and the pharmaceutical compositions comprising same are particularly useful in debriding eschar tissues and in wound healing.
    Type: Grant
    Filed: February 6, 2012
    Date of Patent: September 24, 2013
    Assignee: MediWound Ltd.
    Inventors: Marian Gorecki, Amir Toren
  • Publication number: 20130236445
    Abstract: A method for treating and/or preventing various types of human cancer and neoplastic diseases which is comprised of the administration thereto of an effective amount of Bromelain extract derived from Ananas Comosus and such proteins as ananase, bromelain, comosain, extranase, Inflamen, traumanase, and/or a mixture thereof.
    Type: Application
    Filed: December 16, 2011
    Publication date: September 12, 2013
    Applicant: Garfield Medical Group
    Inventors: Benedict Schue Liao, Alex B. Liao, Austin Lewis Liao, Judy Fu-Chuan Li-Liao, Burton Arthur Liao, Justin Liao, Edward Regean Liao, Robert Liao, Lily Liao, Susan Su-Hsin Tung-Liao, Stanley Leo, Susan Joan Liao-Nieng, Su-Lien Liao-Chen, Ludwig Schue Liao
  • Publication number: 20130216520
    Abstract: Biomass (e.g., plant biomass, animal biomass, microbial, and municipal waste biomass) is processed to produce useful products, such as food products and amino acids.
    Type: Application
    Filed: November 9, 2010
    Publication date: August 22, 2013
    Applicant: XYLECO, INC.
    Inventor: Marshall Medoff
  • Patent number: 8460656
    Abstract: The present invention relates to a phytase which has at least 80% identity to a phytase derived from Citrobacter braakii and comprises at least one alteration when compared to this phytase. These phytase variants have amended, preferably improved, properties, such as thermostability, temperature profile, pH profile, specific activity, performance in animal feed, reduced protease sensitiliby, and/or an amended glycosylation pattern. The invention also relates to DNA encoding these phytases, methods of their production, as well as the use thereof, e.g. in animal feed and animal feed additives.
    Type: Grant
    Filed: March 19, 2007
    Date of Patent: June 11, 2013
    Assignee: Novozymes A/S
    Inventors: Leonardo De Maria, Carsten Andersen, Lars Kobberoee Skov, Mikael Blom Soerensen
  • Publication number: 20130108613
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating an amyloid ?-caused disease, which comprises as an active ingredient a NIa (nuclear inclusion a) protease or a gene carrier containing a nucleotide sequence encoding the NIa protease. The pharmaceutical composition of this invention is very effective to treat a variety of diseases or disorders, inter alia, Alzheimer's disease.
    Type: Application
    Filed: July 23, 2010
    Publication date: May 2, 2013
    Applicant: GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Woo Jin Park, Hye-eun Han
  • Patent number: 8425901
    Abstract: The invention generally features compositions and methods based on the structure-based design of alpha 1-3 N-Acetylgalactosaminyltransferase (alpha 3 GaINAc-T) enzymes from alpha 1-3 galactosyltransferase (a3Gal-T) that can transfer 2?-modified galactose from the corresponding UDP-derivatives due to substitutions that broaden the alpha 3Gal-T donor specificity and make the enzyme a3 GaINAc-T.
    Type: Grant
    Filed: August 22, 2007
    Date of Patent: April 23, 2013
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Pradman K. Qasba, Boopathy Ramakrishnan, Elizabeth Boeggeman, Marta Pasek
  • Patent number: 8420080
    Abstract: We have discovered that the activated phosphorylated form of focal adhesion kinase (hereafter “FAKp”) strengthens the microvascular endothelial cell (EC) junctions that form a barrier in pulmonary endothelia, and the increased barrier helps to prevent acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Thus certain embodiments of the invention are directed to prevention and treatment of ALI and ARDS by administering a therapeutically effective amount of FAKp to subjects at risk of developing or diagnosed as having either ALI or ARDS.
    Type: Grant
    Filed: October 1, 2008
    Date of Patent: April 16, 2013
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Jahar Bhattacharya, Sadiqa K. Quadri, Shonit Das
  • Patent number: 8409840
    Abstract: The present invention pertains in general to Bromelain and particularly to the different active compounds contained in this complex mixture of proteins. The present invention provides recombinant expressed cysteine proteases, which are found in Bromelain. It has been found that the method for expression of the recombinant proteins is superior to the purification from Bromelain itself.
    Type: Grant
    Filed: August 8, 2008
    Date of Patent: April 2, 2013
    Assignee: Ursapharm Arzneimittel GmbH
    Inventors: Rolf Müller, Nora Luniak, Klaus Eschmann
  • Patent number: 8398971
    Abstract: The present invention provides a method of reducing the quanitity of mucus in the respiratory tract of a subject with elevated levels of mucus in said respiratory tract. The method includes administering to the subject a compound or composition containing a therapeutically effective amount of a fusion protein comprising a sialidase or an active portion thereof and an anchoring domain. The therapeutically effective amount comprises an amount of the fusion protein that results in a reduction of the quanitity of mucus in the respiratory tract after administration of the compound or composition when compared to the quantity of mucus present prior to administration of the compound or composition.
    Type: Grant
    Filed: November 5, 2010
    Date of Patent: March 19, 2013
    Assignee: NexBio, Inc.
    Inventors: Fang Fang, David Wurtman, Ron Moss, Michael P. Malakhov
  • Publication number: 20130059001
    Abstract: A therapeutic agent for the treatment of the symptoms of addiction and the method for preparing the therapeutic agent is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using of a biomarker, the presence of chymotrypsin in the gastrointestinal tract to determine the presence of symptoms of addiction, and the likelihood of relapsing into addiction is disclosed.
    Type: Application
    Filed: July 31, 2012
    Publication date: March 7, 2013
    Applicant: Curemark LLC
    Inventor: Joan M. FALLON
  • Publication number: 20130045179
    Abstract: The present invention provides therapy and methods for the treatment and prevention of diseases of cell proliferation such as cancer, benign tumors, and viral diseases such as HIV-AIDS, hepatitis B, hepatitis C and cirrhosis. The methods of this invention consist of the administration to a patient of a combination of effective amounts of agents capable of eradicating the neoplastic cells, while sparing the non-neoplastic cells from cytotoxic side-effects. The agents co-administered in therapeutically effective amounts are: chemotherapeutic agents, apoptotic agents, anti-angiogenic agents, cell differentiation agents, immunomodulating agents, antioxidants, vitamins, microelements, enzymes and natural extracts.
    Type: Application
    Filed: August 15, 2011
    Publication date: February 21, 2013
    Inventors: Mihai Ciustea, Ghiorghe Ciustea
  • Publication number: 20130045196
    Abstract: The present invention is directed to topical enzymatic wound debriding compositions with enhanced enzymatic activity. These compositions comprise a dispersed phase comprising at least one proteolytic enzyme and at least one hydrophilic polyol; and a continuous phase comprising a hydrophobic base.
    Type: Application
    Filed: December 8, 2010
    Publication date: February 21, 2013
    Applicant: HEALTHPOINT, LTD.
    Inventors: Lei Shi, Aleksa Jovanovic, Duncan Aust